Duke optical spinoff company wins Frost & Sullivan North America Award for Excellence in Research
Bioptigen, a spinoff company co-founded by Duke biomedical engineer Joseph Izatt, has won the Frost & Sullivan 2007 North American Optical Coherence Tomography Excellence in Research Award. Bioptigen was singled out for its work in spectral-domain optical coherence tomography (SD-OCT) for ophthalmology.
"This recognition is validation of our vision for the current and future potential of SD-OCT,” said Izatt, professor of biomedical engineering and opthamology, and Chief Technology Officer at Bioptigen. “Our emphasis looking forward is to extend the capabilities of our systems for functional imaging, and to search for new biomarkers of disease processes that will be uniquely accessible through the power of SD-OCT."
In a March 17, 2008 news release, Frost & Sullivan characterized the award winners as “companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze medical device industries in the near future.”
“Bioptigen is honored to receive this recognition from Frost & Sullivan for our developments in spectral domain optical coherence tomography (SDOCT). We are particularly proud of the dedication and passion of the talented team responsible for our progress,” commented Eric Buckland, co-founder and Chief Executive Officer of Bioptigen, Inc.
"Bioptigen and our collaborators in academia and industry recognize the importance of our SD-OCT implementation to pre-clinical research and development as well as to the clinical diagnosis of disease at its very earliest stages," said Buckland.
BioOptics World quoted Frost & Sullivan analyst Rasika Ramachandran in a March 10, 2008 article saying Bioptigen''s OCT imaging system is distinguished by demonstrably superior image quality, real time acquisition, processing and display, and a very high degree of flexibility.
"The company provides research-grade equipment into markets as diverse as ophthalmology, oncology, orthopedics, and genomics, with flexibility in delivery optics and software," Ramachandran was quoted in the article. "At the same time, their platform can be rapidly configured for ease of use in clinical diagnostics. With the unique performance and flexibility of their system, Bioptigen and its technology are poised for success."
Frost & Sullivan is an independent market analysis firm focusing on technology research, market research and economic research.